CNMD vs. INMD, ITGR, TMDX, LIVN, OM, BLFS, MASI, ACAD, ARWR, and PGNY
Should you be buying CONMED stock or one of its competitors? The main competitors of CONMED include InMode (INMD), Integer (ITGR), TransMedics Group (TMDX), LivaNova (LIVN), Outset Medical (OM), BioLife Solutions (BLFS), Masimo (MASI), ACADIA Pharmaceuticals (ACAD), Arrowhead Pharmaceuticals (ARWR), and Progyny (PGNY). These companies are all part of the "medical" sector.
CONMED vs.
CONMED (NYSE:CNMD) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking.
55.2% of InMode shares are held by institutional investors. 7.6% of CONMED shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
CONMED currently has a consensus target price of $130.40, suggesting a potential downside of 0.97%. InMode has a consensus target price of $45.71, suggesting a potential upside of 33.78%. Given InMode's stronger consensus rating and higher possible upside, analysts plainly believe InMode is more favorable than CONMED.
InMode has a net margin of 36.05% compared to CONMED's net margin of -8.53%. InMode's return on equity of 36.35% beat CONMED's return on equity.
In the previous week, InMode had 1 more articles in the media than CONMED. MarketBeat recorded 6 mentions for InMode and 5 mentions for CONMED. InMode's average media sentiment score of 1.19 beat CONMED's score of 0.70 indicating that InMode is being referred to more favorably in the news media.
CONMED has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, InMode has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500.
InMode received 137 more outperform votes than CONMED when rated by MarketBeat users. Likewise, 77.84% of users gave InMode an outperform vote while only 43.75% of users gave CONMED an outperform vote.
InMode has lower revenue, but higher earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
Summary
InMode beats CONMED on 16 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools